# US 10,767,231 B2 · Method for detecting lung cancer using lung cancer-specific methylation marker gene

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,767,231 B2
- Document ID: US10767231B2
- Status: Granted
- Kind: B2
- Application number: 15/814,354
- Filed: 2017-11-15
- Published: 2018-03-08
- Granted: 2020-09-08
- Earliest claimed: 2008-03-14
- Assignees: Genomictree, Inc.
- Applicants: Genomictree, Inc.
- Inventors: Sung Whan An; Young Ho Moon; Tae Jeong Oh
- Web page: https://patentgrep.com/patent/US10767231B2

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/6811: Selection methods for production or design of target specific oligonucleotides or binding molecules
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/154: Methylation markers
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to a method for detecting lung cancer using a lung cancer-specific biomarker, and more particularly to a biomarker for lung cancer diagnosis, which can detect methylation of PCDHGA12 gene whose 5′UTR or exon 1 region is specifically methylated in lung cancer cells, and to a method of detecting lung cancer and the stage of its progression using the biomarker. The diagnostic kit according to the present invention makes it possible to diagnose lung cancer at an early stage in an accurate and rapid manner compared to conventional methods and can be used for prognosis and monitoring of lung cancer and the stage of its progression.

## Claims

### Claim 1

A method for detecting CpG methylation of PCDHGA12 (protocadherin gamma subfamily A, 12), the method comprising the steps of:
(a) isolating a genomic DNA from a clinical sample;
(b) treating the genomic DNA from step (a with bisulfite;
(c) amplifying the bisulfite treated genomic DNA using a primer pair comprising the sequence of SEQ ID NO 433 and SEQ ID NO 434; and
(d) determining hypermethylation in the PCDHGA12 gene.

### Claim 2 (depends on 1)

The method according to claim 1, wherein step (c) is performed by one selected from the group consisting of PCR, methylation specific PCR, real-time methylation specific PCR, PCR using a methylated DNA-specific binding protein, quantitative PCR, pyrosequencing, and bisulfite sequencing.

### Claim 3 (depends on 1)

The method according to claim 1, further comprising probe(s) capable of hybridizing with a methylated CpG of PCDHGA12 comprising at least one or more CpG dinucleotide in a region which hybridizes to the methylated CpG of PCDHGA12.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the probe(s) comprise a probe capable of hybridizing with a methylated CpG of PCDHGA12 comprising the sequence of SEQ ID NO: 435.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said clinical sample is a lung tissue sample.